Kornimate/medical-research-clean huggingface dataset:
sun protection and tanning awareness in rural schools

Conditions: Melanoma; Adolescents

Summary: drawing from prior school-based skin cancer prevention programs, we have adapted intervention materials to target rural high schoolers. program components (including in-class education) will be co-implemented by the research team and participating school staff, with a focus on sustainability beyond the immediate study period. interviews and surveys following initial implementation will evaluate both the effectiveness of the program.

the stars study pilot tests a skin cancer prevention intervention adapted for use in rural schools. participants will be recruited from approximately 14 districts in utah. we have established collaborations with schools, districts, and the utah state board of education (usbe) and they are committed to partnering with us on this project. the research coordinator will contact district-level officials who will be asked to express their support of the study when facilitating the coordinator's contact with school principals and teachers (e.g., health teachers, science teachers). the research coordinator will also directly contact school principals and teachers to discuss participation in the study. an intervention visit, lasting up to 90 minutes, will take place immediately following completion of a baseline survey. this intervention visit may be divided into 2 days, depending on the length of the class periods at the participating schools. during the intervention visit, students will receive general education on skin cancer and skin cancer prevention, complete a skin cancer risk self-assessment tool, and create a sun protection action plan for an outdoor activity. one month later, participants will receive a brief (15-minute) post-intervention survey via email and/or text.

Eligibility criteria:
inclusion criteria: * students are eligible if they are enrolled in a utah high school (e.g. grades 9-12). exclusion criteria: * none

Keywords: prevention school-based intervention skin cancer adolescents rural health
prospective comparative study of the efficacy of common antipyretic treatments in febrile children

Conditions: Fever

Summary: this study will examine in detail the immediate effects of three common treatments given to children with fevers to lower their temperature. each child will be given either ibuprofen, acetaminophen, or a combination, and their temperature monitored at five-minute intervals. the temperature-lowering effects of each treatment will be compared to evaluate which is most effective.

there is no substantial evidence that a fever lower than 41°c is harmful to the welfare of an otherwise healthy child, although they can be dangerous to children already in critical condition \[1,2\]. however, fevers in healthy children commonly cause anxiety in parents and caregivers, so parents and physicians often give antipyretic medications to lower the fever \[3,4\]. ibuprofen and acetaminophen are two of the most commonly used medications in children. most major pediatric medical associations agree about appropriate dosages for children, but give no clear guidelines on whether ibuprofen or acetaminophen should be used \[3,5\]. physicians commonly make the decision between the two based on their personal opinions of the efficacy and safety of the medications, or based on habit \[6\]. survey data shows that more than half of physicians use combinations of both acetaminophen and ibuprofen to treat fever, either simultaneously or on an alternating schedule, with a variety of dosing patterns \[6\]. a majority of physicians believed there were established guidelines supporting this use, but in fact there are not \[6\]. combining the two medications is widely theorized to improve effectiveness, but clinical trials comparing combination treatments to ibuprofen and/or acetaminophen alone have shown inconsistent results \[4,7-12\]. several pharmacodynamic studies have shown that ibuprofen and acetaminophen both produce their largest effects on temperature within the first hour following dosage \[9,10,13-16\]. despite this, only one study has been performed examining the change in temperature at intervals shorter than 30 minutes, and that study used substandard monitoring methods \[10\]. this study will use gold-standard monitoring methods to take temperatures every five minutes through the first one to four hours of treatment. understanding the pattern of temperature change in the acute stages after dosing will help settle the debate about the optimal medication choice for treating childrens' fevers.

Eligibility criteria:
inclusion criteria: * fever between 38 and 41 celsius (inclusive) on presentation to er * assessment by treating physician that patient requires antipyretic treatment exclusion criteria: * known allergy or hypersensitivity to either study medication * received any antipyretic medication in past eight hours * patient requires admission to hospital * co-morbidities indicating increased risk of complication * assessment by treating physician that patient is medically unsuitable for the study

Keywords: acetaminophen ibuprofen
the effect of enoxaparin sodium on the incidence of deep vein thrombosis following electrophysiology studies and radiofrequency ablation.

Conditions: Deep Vein Thrombosis

Summary: the purpose of this study is to assess the effect of the anticoagulant(blood thinner) clexane on the development of leg clots following electrophysiology studies (eps) and or radiofrequency ablation (rfa). people who suffer heart palpitations will sometimes need hospital admission to undergo an electrophysiology study ( and or a radiofrequency ablation)in order to diagnose and or treat their condition. radiofrequency ablation is a procedure to stop abnormal heart rhythms. eps/rfa studies require the puncture of the leg veins . previous experience has shown that following the puncture of leg veins there is a small risk of developing a blood clot in the leg. it is not known whether giving blood thinners (anticoagulants) after the procedure will decrease this risk enoxaparin sodium (clexane) is an anticoagulant used extensively and safely following bone (orthopaedic) surgery to prevent blood clots from developing in the legs


Eligibility criteria:
inclusion criteria: * patients undergoing eps/rfa for the diagnosis and or treatment of svt based on patient history or ecg evidence. exclusion criteria: * patients with a past history of dvt or pe. * patients with a history of clotting disorders * patients with active malignancies * patients requiring full heparinisation during and after the procedure. * chronic atrial flutter and atrial fibrillation ablation
study evaluating the safety and tolerability of combination therapy inotuzumab ozogamicin (cmc-544) and rituximab

Conditions: Lymphoma, B-Cell

Summary: to assess the tolerability and the initial safety profile of inotuzumab ozogamicin (cmc-544) in combination with rituximab in patients with b-cell non-hodgkin's lymphoma (nhl).


Eligibility criteria:
inclusion criteria: * cd20 and cd22-positive, b-cell nhl which has progressed after 1 or 2 prior therapies. * prior therapy must have contained at least one dose of rituximab therapy. patients can not be refractory to rituximab (refractory = pd under treatment or within 6 month * eastern cooperative oncology group (ecog) performance status: 0/ 1. * patients must not have received previous radioimmunotherapy. * patients tolerant to rituximab. * patients must not have received chemotherapy, cancer immunosuppressive therapy, growth factors (except erythropoietin), or investigational agents within 28 days before first dose of test article. exclusion criteria: * candidate for potentially curative therapies * subjects must not have received previous radioimmunotherapy. * subjects with autologous hematopoietic stem cell transplant within the last 6 months

Keywords: b-cell non-hodgkin's lymphoma nhl
efficacy and safety of jak inhibitors in systemic sclerosis-associated interstitial lung disease

Conditions: Systemic Sclerosis; Interstitial Lung Disease

Summary: systemic sclerosis (ssc) is a heterogeneous systemic autoimmune disease with distinct prognosis according to patients. in patients with systemic sclerosis, interstitial lung disease (ild) concerns almost 50 % of patients and represents the main cause of mortality. janus kinases (jak) inhibitors are recent therapies in the field of systemic autoimmune diseases, already approved in patients with rheumatoid arthritis. use of jak inhibitors in systemic sclerosis is based on their anti-inflammatory and anti-fibrotic properties. several preclinical murine models of systemic sclerosis demonstrated the efficacy of ruxolitinib and tofacitinib on cutaneous and pulmonary fibrosis. recently, tofacitinib was evaluated in ssc patients in two clinical studies and showed significant improvement on skin fibrosis. the objective of this study is to evaluate efficacy and safety of jak inhibitors in ssc patients with ild.


Eligibility criteria:
inclusion criteria: * patients with systemic sclerosis according to 2013 acr/eular criteria * patients with interstitial lung disease affecting at least 10 % of the lungs on hrct chest, fvc of at least 40 % of the predicted value and dlco between 30 % and 90 % of the predicted value * use of jak inhibitors exclusion criteria: * patients with an alternative diagnosis of ssc-associated ild (silicosis, sarcoidosis, lung cancer or other significant lung abnormalities) * patients with pulmonary arterial hypertension defined on right heart catheterization
immunophenotype role in the evaluation of clinical response

Conditions: Multiple Myeloma; Post Allografting

Summary: the study proposed by sscvd allogeneic stem cells of this hospital provides for the collection of a series composed of patients with multiple myeloma undergoing allogeneic stem cell transplants at our center in the period 2000-2011. this collection is carried out with retrospective investigation , through the review of paper and electronic records and data cards already collected as part of clinical trials conducted by our own division and approved by the ethics committee of management. the purpose of data collection is particularly retrospective analysis of the incidence of extramedullary relapse , the response in flow cytometry immunophenotypic and clinical response of the disease , will also be taken into consideration for overall survival ( os) , event-free survival (efs) , the cumulative incidence of treatment-related mortality and graft- versus-host disease ( gvhd ), acute and chronic. the data were processed in a completely anonymous and as provided by law. the results of the study will not result in any diagnostic or therapeutic intervention on patients still alive.


Eligibility criteria:
inclusion criteria: adult patients with multiple myeloma undergoing allogeneic stem cell transplantation in the period 2000-2011 at the university transplant center of the division of hematology. were taken into account both donor transplants voluntary blood relative. exclusion criteria: patients who died early after allogeneic transplantation (\<3 months) in which has not been evaluated disease status. in the evaluation of the response of immunophenotypic disease were excluded from the analysis of bone marrow aspirate samples with low cellularity.
comparison of 2 low molecular weight heparin as a thromboprophylaxis postpartum

Conditions: Venous Thromboembolic Diseases

Summary: the use of a new generation low molecular weight heparin (bemiparin)and the well known lmwh (enoxaparin) after caesarean sections and vaginal deliveries in a risky group patients for venous thrombosis.

venous thromboembolism (vte) is the leading cause of maternal mortality and morbidity in the developed and developing world. pulmonary embolism and deep vein thrombosis are the two components of a single disease called deep vein thrombosis (dvt). pregnancy associated with an average 5 to 10 fold increase in the risk of vte compared with non-pregnant women. the highest incidence occurring during the post partum period. there are many researches done a broad on the effect of lmwh to decrease the incidence of vte after caesarean section using the two lmwh (enoxaparin and bemiparin) alone but not in one research comparing both of them alone and both together against a control group. also according to our knowledge there are no published literature on thromboprophylaxis after vaginal delivery

Eligibility criteria:
inclusion criteria: * presence of risk factors for venous thromboembolism * any parity * mode of delivery:vaginal, emergency and elective caesarean section * no any contraindications for heparin exclusion criteria: * active antenatal or postpartum vaginal bleeding. * placenta previa * thrombocytopenia * sever renal or liver diseases * uncontrolled sever hypertension * any patient who is already on heparin during pregnancy

Keywords: deep vein thrombosis pulmonary embolism low molecular weight heparin enoxaparin bemiparin
transcutaneous auricular vagus nerve stimulation on dizziness & balance in elderly population

Conditions: Vestibular Diseases

Summary: the objective of the study is to determine the effects of transcutaneous auricular vagus nerve stimulation on dizziness and balance on elderly population with unilateral vestibular hypofunction. patients will be divided into experimental and control group. randomized participants will be allocated into control and experimental group. intervention group a received vagus nerve stimulation (vns) and caw thorne cooksey exercise while group group b received caw thorne cooksey exercise only. both groups received intervention of 30 minutes daily for 4 weeks (16 sessions). assessment was done at the baseline, after 2 weeks and after 4 weeks

vestibular hypofunction is also known as vestibulopathy or vestibular dysfunction. it may be unilateral affecting one side or a bilateral vestibulopathy having symptoms on both sides.typically, vestibular dysfunction results in incapacitating symptoms including imbalance, dizziness, and/or oscillopsia. symptoms of postural instability and unsteadiness of gait, which aggravate in low light and on uneven terrain, may be given by the patient. the symptoms of the patient may go away while they are sitting or lying still. without any obvious symptoms, it may be quiet vestibular hypofunction is a common condition among the elderly population and is associated with a high risk of falls and other balance-related problems. dizziness and balance problems can significantly impact the quality of life of elderly individuals, leading to a loss of independence and increased risk of injury. cawthorne cooksey exercise is a well-established and effective rehabilitation program for individuals with vestibular hypofunction. transcutaneous auricular vagus nerve stimulation has also been shown to have promising effects on balance and dizziness. however, the combined effect of these two interventions has not been extensively studied.

Eligibility criteria:
inclusion criteria: 1. able to give consent 2. age 60 and above 3. diagnosed patient of unilateral(left) vestibular hypo function 4. both genders 5. bbs with 20-41 exclusion criteria: 1. patient with any neurological impairment (epilepsy, stroke als etc.) 2. central cause of vestibular hypo function 3. history of vestibular neuritis, concussion, head injury or tumor.

Keywords: vns, cawthorne exercises
multimodal monitoring in patients with spontaneous intracerebral hemorrhage

Conditions: Cerebral Hemorrhage

Summary: spontaneous intracerebral bleeding also known as spontaneous intracerebral hemorrhage (sich) constitute 10-15 % of all apoplexies. the prognosis is considerably worse than it is for the larger population of patients suffering from cerebral thrombosis. development of brain edema seemingly contributes to the disadvantageous prognosis. however, the mechanisms behind is only understood fragmentarily. by using multimodal neuro monitoring, the investigators seek to investigate electrophysiological and metabolic processes, which seem to accompany the formation of edema and clinical deterioration in patients suffering from sich.


Eligibility criteria:
inclusion criteria: * diagnosis: spontaneous intracerebral hemorrhage verified by ct * clinical indication for craniotomy or craniectomy * admitted to the hospital within 24 hours from assumed ictus * age over 18 years exclusion criteria: * pregnancy

Keywords: eeg cortical spreading depression cerebral hemorrhage mirna reactivity in eeg multimodal monitoring
safety of a single dose of moxidectin compared with ivermectin in individuals living in onchocerciasis endemic areas and in individuals living in onchocerciasis endemic areas with high levels of lymphatic filariasis co-endemicity receiving concomitant albendazole

Conditions: Onchocerciasis

Summary: the purpose of this phase 3b study is to determine the safety of a single dose of moxidectin, compared to a single dose of ivermectin, in individuals living in onchocerciasis endemic areas and in individuals living in onchocerciasis endemic areas with high levels of lymphatic filariasis co-endemicity receiving concomitant albendazole.


Eligibility criteria:
inclusion criteria: 1. provision of written informed consent, or assent with parental or guardian written consent\* 2. known o. volvulus skin microfilariae density ≥0 microfilariae/mg skin (participants ≥12 years of age only). 3. living in an onchocerciasis endemic area. 4. age ≥4 years 5. all female participants of childbearing potential must commit to the use of a reliable method of birth control until 3 months after administration of investigational product (month 3). \* expression of 'deliberate objection' will be the basis for assessing assent of children aged ≥ 4 to \<6 years exclusion criteria: 1. pregnant or breast-feeding. 2. any concurrent condition that, in the opinion of the investigator, would preclude evaluation of response to treatment or would pose undue risk to the participant's health. 3. has received ivermectin or oral diethylcarbamazine (dec) within 30 days of baseline. 4. has received treatment with an investigational agent within the 30 days (or 5 half-lives, whichever is longer) prior to planned investigational product administration. 5. known or suspected allergy to ivermectin or moxidectin or their excipients and, in areas with high levels of lf co-endemicity, known or suspected allergy to albendazole and its excipients. 6. self-reported planned or ongoing activities within the study period that would make it unlikely that the participant will be available for follow-up examinations. 7. infection with loa loa. 8. height \<90 cm.
carpal tunnel syndrome release using psu retractor

Conditions: Carpal Tunnel Syndrome

Summary: the investigators study aims to evaluate both efficacy and safety of carpal tunnel release using limited incision with the psu retractor compared to standard incision. the investigators will do a randomized controlled trial in 60 patients with carpal tunnel release and evaluate for outcome regarding pain, vas score, return to work time, cts score and complications at 6 months.


Eligibility criteria:
inclusion criteria: * patients diagnosed as carpal tunnel syndrome who failed to conservative treatment 3 months exclusion criteria: * underlying disease such as : dm, neuropathy * previous wrist or hand surgery in the same side * previous wrist and hand trauma * pregnancy

Keywords: carpal tunnel syndrome surgery psu retractor carpal tunnel syndrome who failed to conservative treatment
association of brain derived neurotrophic factor (bdnf) rs6265 gene polymorphism with susceptibility to epilepsy

Conditions: Epilepsy

Summary: epilepsy is a common neurological condition that affects people of all ages.recent studies found that epilepsy is associated with several chromosomal regions, where mutations in these regions cause neurological dysfunction. bdnf which is the most ample neurotropic factor in the cns, has survival and growth promoting roles in a variety of neurons. it has been shown to promote excitatory (glutamatergic) synapses while weakening inhibitory (gabaergic) ones. a nonsynonymous g to a single-nucleotide polymorphism (snp) exists at position 196 of exon 2 (rs6265), which results in valine (val) to methionine (met) substitution. this polymorphism affects intracellular packaging of pro-bdnf, its axonal transport and in turn, activity-dependent secretion of bdnf at the synapse.

epilepsy was defined as the separate occurrence of two or more unprovoked seizures, manifested by involuntary motor, sensory, or autonomic, alone or in combination, and not diagnosed as neonatal or febrile seizures. despite extensive studies, the molecular causes of the disease are not yet discovered completely. a functional imbalance between excitatory (transmitted by glutamate) and inhibitory signals (transmitted by γ-amino butyric acid or gaba) in neural cells has been regarded as a putative contributing factor in epilepsy. the brain-derived neurotropic factor (bdnf) encodes a small dimeric protein which is the most ample neurotropic factor in the cns.it has been shown to promote excitatory (glutamatergic) synapses while weakening inhibitory (gabaergic) ones.any interference with the bdnf signaling pathway may negatively affect downstream neuronal functions and cause neuronal diseases. a nonsynonymous g to a single-nucleotide polymorphism (snp) exists at position 196 of exon 2 (rs6265), which results in valine (val) to methionine (met) substitution at codon 66 (val66met), changing the 5' proregion of the human bdnf protein. this polymorphism affects intracellular packaging of pro-bdnf, its axonal transport and in turn, activity-dependent secretion of bdnf at the synapse

Eligibility criteria:
inclusion criteria: • epileptic patients aged more than 1 year and less than 15 year who recently had seizures over a period of one year exclusion criteria: * patients \> 15 years old or less than 1 year. * patients that have epilepsy as a result of head injuries, brain tumors , exposure to low oxygen during birth or infections such as meningitis or encephalitis . * patients that have no sufficient medical records or unreliable seizure frequency, * patients with developmental disorders such as autism and neurofibromatosis

Keywords: bdnf in epileptic patients
follow-up study of subcutaneous immune globulin in patients requiring igg replacement therapy (japan study)

Conditions: Primary Immune Deficiency Disorder

Summary: the objective of this study is to assess the long-term safety, tolerability, and efficacy of igpro20 in subjects with primary immunodeficiency (pid) as a follow-up to the pivotal study zlb06_002cr (nct01199705).


Eligibility criteria:
inclusion criteria: * subjects who have participated in study zlb06_002cr and who have tolerated igpro20 well. * written informed consent by the subject/parent/legally acceptable representative. written assent for an underage subject (≥7 years at the time of obtaining informed consent), as far as possible. exclusion criteria: * ongoing serious bacterial infections (sbis) (pneumonia, bacteremia/septicemia, osteomyelitis/septic arthritis, bacterial meningitis, or visceral abscess) at the time of the first infusion. * hypoalbuminemia, protein-losing enteropathies, and any proteinuria (known total urine protein concentration \>0.2 g/l or urine protein ++ by dipstick). * pregnancy or nursing mother. * participation in a study with an investigational medicinal product (imp) within 3 months prior to enrollment except for zlb06_002cr. * subjects who are planning to donate blood during the study. * re-entry of subjects previously participating in the current follow-up study. * known or suspected antibodies to the imp, or to excipients of the imp.

Keywords: immune globulin subcutaneous scig primary immunodeficiency pid